Skip to Content

Nicox SA Share from reverse split NICXF

Morningstar Rating
$0.44 −0.20 (30.84%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

NICXF is trading at a 831% premium.
Price
$0.44
Fair Value
$9.23
Uncertainty
Extreme
1-Star Price
$75.70
5-Star Price
$9.39
Economic Moat
Htjt
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NICXF is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.64
Day Range
$0.440.44
52-Week Range
$0.440.89
Bid/Ask
$0.44 / $0.52
Market Cap
$22.07 Mil
Volume/Avg
100 / 100

Key Statistics

Price/Earnings (Normalized)
Price/Sales
3.50
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Nicox SA is an international company specializing in ophthalmology developing solutions aimed at maintaining vision and improving eye health. The company's program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It is also conducting research on NCX 1728, a NO-donating phosphodiesterase 5 inhibitor, in retinal diseases. NCX 4251, a patented ophthalmic suspension of fluticasone propionate nanocrystals, for topical ocular application for dry eye, is being developed by Ocumension Therapeutics in China. Nicox generates revenue from VYZULTA in glaucoma and ZERVIATE in allergic conjunctivitis.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
29

Valuation

Metric
NICXF
Price/Earnings (Normalized)
Price/Book Value
0.45
Price/Sales
3.50
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
NICXF
Quick Ratio
8.60
Current Ratio
8.97
Interest Coverage
−12.79
Quick Ratio
NICXF

Profitability

Metric
NICXF
Return on Assets (Normalized)
−29.67%
Return on Equity (Normalized)
−57.35%
Return on Invested Capital (Normalized)
−33.77%
Return on Assets
NICXF
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
NrmqyyfjfSqjm$626.5 Bil
Vertex Pharmaceuticals Inc
VRTX
VwrsyyqfpZwqvrbj$122.2 Bil
Regeneron Pharmaceuticals Inc
REGN
HhwwnbfCwjfbj$115.2 Bil
Moderna Inc
MRNA
GmrfbcddFxpb$52.8 Bil
argenx SE ADR
ARGX
LpkxbwlwdQzl$22.6 Bil
BioNTech SE ADR
BNTX
LbfdstjPgc$21.3 Bil
Alnylam Pharmaceuticals Inc
ALNY
KtcwtkqSgzgtx$19.9 Bil
Biomarin Pharmaceutical Inc
BMRN
YrhnzvyqFlyfbj$16.1 Bil
United Therapeutics Corp
UTHR
QrcxfsmnqBks$13.2 Bil
Incyte Corp
INCY
WtdyvflcmBrkvbk$12.4 Bil

Sponsor Center